NKGen Biotech

Frontotemporal Dementia (FTD) is a devastating neurodegenerative disease that remains relatively unknown to the broader public, despite its profound impact on patients and families. FTD primarily affects the areas of the brain responsible for behavior, personality, language, and decision-making, often occurring at a younger age than other forms of dementia.

During FTD Awareness Week, NKGen is joining the effort to raise awareness of FTD, the challenges faced by those living with the disease, and the need for greater attention and research to help patients and their families.

As a company focused on advancing treatments for neurodegenerative diseases, we recognize the importance of greater awareness and continued research into conditions like FTD, where significant unmet needs remain.

This week, we stand with the FTD community in helping raise awareness and understanding of this disease.

Today is World Alzheimer’s Day.

Earlier this month, we shared the global impact of Alzheimer’s and other forms of dementia. Today, we want to share what this day means to us at NKGen.

As a clinical-stage biotechnology company, we are actively working to advance neuroscience research and explore potential new approaches for people affected by Alzheimer’s disease and other neurodegenerative diseases.

For patients, families, and caregivers, the need for better options is real and urgent. That is why we remain committed to the research and clinical development needed to move the science forward.

Today, we stand with the Alzheimer’s community and with everyone working toward a better future.

NKGen Biotech to Present at the 4th Great Bay Cell & Gene Therapy Forum

On September 23, 2026, NKGen Biotech (OTC: NKGN) Chairman and CEO Paul Y. Song, M.D., will present on the company’s investigational NK cell therapy, troculeucel, including protein biomarker findings and clinical experience in neurodegenerative diseases.

Read the full press release here: https://bit.ly/3T0NIMw

$NKGN

NKGen Biotech (OTC:NKGN) will present on the potential of the Company's lead investigational program, troculeucel, in neurodegenerative diseases at Biologics Manufacturing Korea 2026.

Dr. Paul Y. Song, M.D. will highlight the development of troculeucel in neurodegenerative diseases, drawing on clinical experience and biomarker findings and offering perspective on the regulatory landscape in Asia and its relevance to the program's development.

Read the full press release: https://bit.ly/4ytGzTR

$NKGN

NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 SANTA ANA, Calif., September 10, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced t...

September is World Alzheimer’s Month. A time to raise awareness, challenge stigma, support those living with dementia, and recognize the millions of families and caregivers affected around the world.

Alzheimer’s disease continues to have a profound impact on individuals, families, caregivers, and healthcare systems. At the same time, advances in research are creating new possibilities for earlier diagnosis and treatments that may help slow disease progression.

At NKGen Biotech, we are committed to advancing research in Alzheimer’s disease and exploring new approaches that could one day make a meaningful difference for patients and their families.

This month, we stand with the global Alzheimer’s community and everyone working toward a future with better understanding, better care, and better treatment options.

Together, we can raise awareness, support those affected, and advance the search for better solutions.

June is Alzheimer's & Brain Awareness Month.

According to the 2026 Alzheimer's Association Facts & Figures Report, more than 7 million Americans are living with Alzheimer's disease, highlighting the ongoing need for awareness, education, and scientific research.

This month, we recognize those affected by Alzheimer's disease and support efforts to advance understanding of brain health and neurodegenerative diseases.

NKGen Biotech (OTC:NKGN) announces the activation of three additional U.S. clinical sites for its ongoing Phase 2 study of troculeucel in moderate Alzheimer's disease, expanding patient access and supporting enrollment efforts across multiple regions.

Learn more: https://bit.ly/4dkqNmI

$NKGN

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease. SANTA ANA, Calif., May 19, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical...

This May, we recognize ALS Awareness Month alongside the global community. ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative condition that affects nerve cells responsible for movement, gradually impacting the ability to move, speak, eat, and breathe.

We acknowledge patients, families, and caregivers affected by ALS and recognize the importance of continued scientific research to better understand neurological diseases. NKGen remains committed to advancing neurodegenerative disease research to help patients with limited treatment options.

NKGen Biotech, Inc. (OTC: NKGN) will present at the 8th Annual Neuroimmunology Drug Development Summit in Boston on Thursday, April 16, 2026, at 11:00 AM ET.

NKGen CEO, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). The presentation will include an overview of the Company's expanding mechanistic dataset, including evidence that troculeucel selectively targets autoreactive T cells and may modulate key neuroinflammatory pathways implicated in disease progression. Dr. Song will also review clinical observations from early-stage studies, including encouraging biomarker trends and reductions in neuroinflammatory signals measured in cerebrospinal fluid.

Read the full press release: https://nkgenbiotech.com/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimers-and-frontotemporal-dementia-at-the-neuroimmunology-drug-development-summit/

$NKGN

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit SANTA ANA, Calif., April 9, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that i...

April is Parkinson’s Disease Awareness Month, a time to recognize the individuals and families affected by this progressive neurodegenerative disease and to highlight the importance of continued research and innovation across the field.

At NKGen Biotech, we are dedicated to advancing science in neurodegenerative diseases and supporting efforts that deepen understanding and drive future therapeutic progress. While there is still much to learn, ongoing collaboration across the scientific and medical communities continues to move the field forward.

This month, we stand with patients, caregivers, clinicians, and advocates to raise awareness and reinforce the importance of sustained investment in Parkinson's disease research and education.